3results about How to "Reduce degeneration" patented technology

This invention discloses the application of a Cav3.2 inhibitor in the preparation of a drug for treating intervertebral disc degeneration. Z944 can block the activation level of Cav3.2 in nucleus pulposus cells, effectively alleviating lipid metabolism disorders and cellular biological behavior disorders induced by abnormal mechanical stress, and ultimately reducing intervertebral disc degeneration. This demonstrates that Z944 is a drug with clinical application potential, which can be used to alleviate the pain and burden of patients with low back pain and improve their quality of life.

The application discloses a kind of nanocomposite hydrogel for treating osteoarthritis and its preparation method and application, the nanocomposite hydrogel includes cerium dioxide nanoparticles, the cerium dioxide nanoparticles are modified with hyaluronic acid;Ergothioneine is loaded on hyaluronic acid modified cerium dioxide nanoparticles to form nanocomposite EGT-CeO2@HA;And temperature-sensitive hydrogel carrier, the nanocomposite EGT-CeO2@HA is uniformly dispersed in the temperature-sensitive hydrogel carrier.This composite hydrogel can activate ATF4-dependent pro-survival autophagy pathway, reduce cartilage cell inflammatory damage, and improve cartilage degeneration.

This invention belongs to the field of biomedical technology and relates to the application of PAX8 gene inhibitors in the preparation of drugs for treating optic nerve degeneration. The PAX8 gene inhibitor is a shRNA that targets and inhibits the PAX8 gene or a vector expressing a shRNA that targets and inhibits the PAX8 gene. The vector uses the astrocyte-specific promoter gfabc1d. Experiments have demonstrated that by specifically inhibiting PAX8 expression in astrocytes, axoplasmic transport obstruction in the optic nerve is relieved, optic nerve degeneration is alleviated, and a new gene therapy strategy is provided for the protective treatment of optic nerve degeneration in glaucoma.